23andMe CEO Anne Wojcicki discussed the company’s recent data-sharing deal with GlaxoSmithKline during TechCrunch’s Disrupt show.
The genetics testing company’s deal with GSK would give the drugmaker exclusive rights to 23andMe’s huge database of customer information to create drug targets, according to a TechCrunch report. GSK reportedly has a $300 million stake in the company as part of the four-year deal.
While the 23andMe has previously shared information on some five million individuals with GSK and six other firms, the deal would let GSK alone access the anonymized customer data.
To read the full report on TechCruch, click here.